Member Info for jonbhoy

Wow you caught on quickly

They have dropped us again soon be 1p as I forecast 2 weeks ago slowly but surely walking us down

just a feeling of changing sentiment

can't wait

and the sp is still down so tell me this is not manipulated

spinning stories out

What’s going on with this board showing all trades as sells2days in a row

when was this presentation filmed I would be more interested to listen to the presentation from shares mag last week.

silly question do we think that big buy will allow us to open up tomorrow

its ok owning 100% of the compounds but they have to be proven to work no point owning if it's broken

had a look at the slides that were released I don't pretend to understand all of it but this: Subjects on 5mg/kg analysis not yet completed – showing tolerability and modulation of related factors and a >40-50% PSA reduction suggested , could be very interesting maybe just maybe this will help get things moving.

surely if everything the bod has told us is true this must come good

somethings definitely wrong here

if its that positive why is the sp continually falling

Align also shit on the shareholders who gave them their support so why would anyone trust anything they say

dont know about align research except it looks to me that they are vein paid by val whether its by begin given shares or cash to produce favourable reports but I do know its just all a rehash of old news.align research are not friends of investors here they are in bed with val, don't listen to them.

this must be the longest closed period in the history of trading hence no director buying maybe one day after we have had another consolidation and they finally stop bleeding us dry they might put some of their own money in here after all christmass is not that far away.

another late trade from a couple of days ago plus the 1.8 mill bought today and yet they still see fit to have dropped the sp this aim is surely a sewer of sh*t.

Among featured M&A news last week, US devices company Boston Scientific made a $4.24 billion bid for UK-based specialty pharma firm BTG, and there was also talk that US immuno-oncology company Tesaro may be putting itself up for sale. On the research front, there was disappointment for Germany’s Merck KGaA and US partner Pfizer as their immune checkpoint inhibitor Bavencio (avelumab) failed to meet endpoints in a Phase III ovarian cancer study. But there was better news for Danish diabetes care giant Novo Nordisk, with positive cardiovascular outcomes with its oral semaglutide in the PIONEER 9 trial.

Boston bid for BTG shows dreams can come true

Analysts who had been predicting a gloomy future for BTG will have been eating their words last Tuesday. The medtech big hitter Boston Scientific has agreed to pay 840 pence per share for the UK group, a valuation not seen since 2001, commented Madeleine Armstrong on Vantage, the editorial arm of the Evaluate group. This surprise outcome is a huge coup for investors in the UK group, which has struggled to find focus after a string of acquisitions.

Boston is not interested in BTG’s older, speciality pharma products, such as the snake venom antidote CroFab. The Marlborough, Massachusetts-based company wants to get its hands on devices for cancer and pulmonary embolism.

BTG gained these via more recent purchases, and has thus managed to reduce reliance on Zytiga, on which the company receives substantial royalties from Johnson & Johnson. The prostate cancer drug is set to come off patent soon in the US, meaning that BTG's main revenue stream is drying up.

In the coming years, most valuable product is expected to be its Therasphere radiotherapy microspheres, used to treat liver cancer. This product makes up the bulk of the group’s interventional oncology sales, which are forecast to hit around $330m by 2022.

The takeout means that the UK will lose one of its few small-mid cap life science companies, but in reality BTG has been struggling to make headway for years. Investors will be forgiven for thinking Christmas has come early. Shareholders in other hotly-tipped takeout targets can live on in hope.

UNCANNY if you keep adding I hope you enjoy great success with your investment but personally Iam still not convinced with the bod and their smoke and mirrors information and investor meetings Ihave lost count of the number of these meet ins and Rns's that they have taken place in or released without actually saying anything.I had a post removed yesterday for saying the BOD are always speaking without actually saying anything of worth.